Yahoo
    Frankfurt - Delayed Quote EUR

    BioNTech SE (22UA.F)

    78.05 +0.45 (+0.58%)
    As of 2:13:04 PM GMT+1. Market Open.
    22UA.F Q3 2026 earnings call
    November 3, 2026 at 2 PM GMT+1
    Loading Chart for 22UA.F
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook

    BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook
    Zacks 4d ago
    BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety Warning

    BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety Warning
    Simply Wall St. 4d ago
    Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

    Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
    24/7 Wall St. 4d ago
    Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?

    Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?
    Zacks 5d ago
    The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings

    The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
    24/7 Wall St. 6d ago
    Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

    Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
    24/7 Wall St. 7d ago
    BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

    BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
    GlobeNewswire 7d ago
    BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?

    BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?
    Simply Wall St. 8d ago
    BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach

    BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach
    Simply Wall St. 8d ago
    BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

    BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
    GlobeNewswire 8d ago
    Moderna’s Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.

    Moderna’s Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.
    Barrons.com 9d ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: